Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.
We measured the serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH) in 82 male patients with primary gout whose serum uric acid was significantly higher than that of 41 normal control male subjects (8.8 +/- 0.2 vs 5.6 +/- 0.2 mg/dL, p < 0.001). The serum 1,25(OH)2-vitamin D3 concentration was significantly lower in the patients with gout compared with the control subjects (39.6 +/- 1.4 vs 44.8 +/- 1.7 pg/mL, p < 0.05), while no differences were observed between the two groups in either the serum concentration of 25(OH)-vitamin D3 or PTH. The administration of uric acid lowering agent to the patients for 1 year caused a significant increase in their serum 1,25(OH)2-vitamin D3 concentration which was associated with a significant decrease in their serum uric acid concentration. In contrast, the serum concentrations of 25(OH)-vitamin D3 and PTH were not affected by these drugs. These results suggest that uric acid per se may directly decrease the serum concentration of 1,25(OH)2-vitamin D3 in patients with gout by inhibiting 1-hydroxylase activity.
Takahashi
S
S
Third Department of Internal Medicine, Hyogo College of Medicine, Japan.
Yamamoto
T
T
Moriwaki
Y
Y
Tsutsumi
Z
Z
Yamakita
J
J
Higashino
K
K
D000493:Allopurinol / Q000627:therapeutic use; D002112:Calcifediol / Q000097:blood; D002117:Calcitriol / Q000097:blood*; D006073:Gout / Q000097:blood* / Q000188:drug therapy; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D012016:Reference Values; D014527:Uric Acid / Q000097:blood*
D006074:Gout Suppressants; D010281:Parathyroid Hormone; D014527:Uric Acid; D000493:Allopurinol; D002117:Calcitriol; D002112:Calcifediol